• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    PACS Group Announces Appointment of Evelyn Dilsaver to Serve as Independent Board Director

    5/13/24 7:31:00 PM ET
    $HQY
    $QDEL
    $TPX
    Real Estate
    Real Estate
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $HQY alert in real time by email

    PACS Group, Inc. (NYSE:PACS) ("PACS" or the "Company") announced today that Evelyn Dilsaver has been appointed to serve as a member of its Board of Directors. "We're thrilled to have Evelyn join our board," said Jason Murray, PACS Chairman and CEO. "She has great experience as an accounting and finance professional, not to mention her work on the boards of several other public companies. She'll bring added perspective and expertise to the board as we work to guide PACS going forward."

    "I'm excited to join the PACS Board and assist the company in continuing its mission to provide quality skilled nursing care. I look forward to great things ahead for the company," added Ms. Dilsaver.

    Ms. Dilsaver also serves on the boards of directors of Tempur Sealy International (NYSE:TPX), HealthEquity, Inc. (NASDAQ:HQY) and QuidelOrtho (NASDAQ:QDEL). Ms. Dilsaver was President and Chief Executive Officer of Charles Schwab Investment Management from July 2004 until September 2007. Prior to that, she held various senior management positions with The Charles Schwab Corporation. Ms. Dilsaver is a certified public accountant and holds a B.S. degree in accounting from California State University-Hayward.

    Ms. Dilsaver is an independent director under applicable NYSE and SEC rules. Her appointment now makes the PACS Board of Directors majority independent. Ms. Dilsaver's committee appointments will be considered at a later date.

    About PACS Group

    PACS Group, Inc. is a holding company investing in post-acute healthcare facilities, professionals, and ancillary services. Founded in 2013, PACS Group is one of the largest post-acute platforms in the United States. Its independent subsidiaries operate over 200 post-acute care facilities across nine states serving over 20,000 patients daily.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240513694766/en/

    Get the next $HQY alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HQY
    $QDEL
    $TPX

    CompanyDatePrice TargetRatingAnalyst
    HealthEquity Inc.
    $HQY
    5/22/2025$105.00 → $112.00Outperform
    RBC Capital Mkts
    QuidelOrtho Corporation
    $QDEL
    5/8/2025$44.00Hold → Buy
    Jefferies
    HealthEquity Inc.
    $HQY
    3/25/2025$120.00 → $115.00Outperform → Strong Buy
    Raymond James
    Tempur Sealy International Inc.
    $TPX
    2/5/2025Mkt Perform → Outperform
    William Blair
    Tempur Sealy International Inc.
    $TPX
    2/3/2025$67.00 → $80.00Neutral → Outperform
    Wedbush
    QuidelOrtho Corporation
    $QDEL
    12/11/2024$44.00 → $50.00Neutral → Buy
    Citigroup
    QuidelOrtho Corporation
    $QDEL
    12/10/2024$43.00Hold
    Jefferies
    HealthEquity Inc.
    $HQY
    12/4/2024$126.00Outperform
    Mizuho
    More analyst ratings

    $HQY
    $QDEL
    $TPX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Blaser Brian J. bought $249,878 worth of shares (6,033 units at $41.42) (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    12/13/24 4:12:57 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Busky Joseph M bought $99,663 worth of shares (2,150 units at $46.35) (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    2/26/24 6:48:23 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $HQY
    $QDEL
    $TPX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    QuidelOrtho Launches Certified Analyzer Program

    Initiative to expand testing access to underserved U.S. communities SAN DIEGO, Aug. 13, 2025 /PRNewswire/ -- QuidelOrtho Corporation has launched a Certified Analyzer Program, an innovative initiative designed to expand access to high-quality diagnostic testing in rural and community hospitals across the United States. Tailored for clinics, physician office labs and small hospitals with fewer than 100 beds, the program offers certified VITROS™ analyzers that deliver proven reliability and quality results, with award-winning service, at a fraction of the cost. "Our mission is r

    8/13/25 3:00:00 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    HealthEquity Announces Dates to Report Second Quarter Earnings and Presentations at Investor Conferences

    DRAPER, Utah, Aug. 06, 2025 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ:HQY) ("HealthEquity" or the "Company"), the nation's largest health savings account ("HSA") custodian, today announced plans to release its second quarter of fiscal 2026 financial results following the close of regular stock market trading hours on Tuesday, September 2, 2025. Following the news release, HealthEquity management plans to host a conference call for investors on Tuesday, September 2, 2025, at 4:30 p.m. Eastern Time during which management will review the Company's financial results. HealthEquity Second Quarter Fiscal Year 2026 Results Conference CallDate: September 2, 2025Time: 4:30 p.m. Eastern Time /

    8/6/25 9:00:00 AM ET
    $HQY
    Real Estate

    QuidelOrtho Reports Second Quarter 2025 Financial Results

    ― Labs revenue grew 4% as reported and 5% in constant currency ―― Adjusted EBITDA margin improved by 330 basis points; Achieved $100 million annualized cost savings from initiatives announced in 2024 ― ― Company reiterates full-year 2025 financial guidance ― Second Quarter 2025 Results(all comparisons are to the prior year period) Total revenue was $614 million, as reportedNon-respiratory revenue was $567 million, a decrease of 2% both as reported and in constant currency; excluding Donor Screening, non-respiratory revenue grew 1% in constant currencyLabs revenue grew 4% as reported and 5% in constant currencyImmunohematology revenue grew 4% as reported and 3% in constant currencyRespiratory

    8/5/25 4:10:00 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $HQY
    $QDEL
    $TPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    FOUNDER AND VICE CHAIRMAN Neeleman Stephen gifted 3,000 shares (SEC Form 4)

    4 - HEALTHEQUITY, INC. (0001428336) (Issuer)

    7/31/25 4:23:15 PM ET
    $HQY
    Real Estate

    Director Buechler Kenneth F exercised 9,215 shares at a strike of $15.74, increasing direct ownership by 10% to 101,921 units (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    7/17/25 4:09:04 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    New insider Gathright Michael claimed ownership of 27,006 shares (SEC Form 3)

    3 - HEALTHEQUITY, INC. (0001428336) (Issuer)

    7/14/25 2:27:15 PM ET
    $HQY
    Real Estate

    $HQY
    $QDEL
    $TPX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by QuidelOrtho Corporation

    SCHEDULE 13G/A - QuidelOrtho Corp (0001906324) (Subject)

    8/7/25 3:58:39 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    QuidelOrtho Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - QuidelOrtho Corp (0001906324) (Filer)

    8/5/25 4:11:59 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by QuidelOrtho Corporation

    SCHEDULE 13G/A - QuidelOrtho Corp (0001906324) (Subject)

    7/29/25 2:22:09 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $HQY
    $QDEL
    $TPX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts resumed coverage on HealthEquity with a new price target

    RBC Capital Mkts resumed coverage of HealthEquity with a rating of Outperform and set a new price target of $112.00 from $105.00 previously

    5/22/25 9:53:52 AM ET
    $HQY
    Real Estate

    QuidelOrtho upgraded by Jefferies with a new price target

    Jefferies upgraded QuidelOrtho from Hold to Buy and set a new price target of $44.00

    5/8/25 9:44:58 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    HealthEquity upgraded by Raymond James with a new price target

    Raymond James upgraded HealthEquity from Outperform to Strong Buy and set a new price target of $115.00 from $120.00 previously

    3/25/25 8:22:31 AM ET
    $HQY
    Real Estate

    $HQY
    $QDEL
    $TPX
    Leadership Updates

    Live Leadership Updates

    View All

    HealthEquity Reports Year-End Sales Metrics

    DRAPER, Utah, Feb. 18, 2025 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ:HQY) ("HealthEquity" or the "Company"), the nation's largest health savings account ("HSA") custodian, today announced its HSAs, HSA Assets and Total Accounts as of its fiscal year ended January 31, 2025. The Company also affirmed its guidance for fiscal 2025 and 2026, provided an updated HSA cash repricing schedule, and announced upcoming events and presentations. The total number of HSAs as of January 31, 2025 was 9.9 million, an increase of 14%, from 8.7 million as of January 31, 2024. The Company closed its fiscal year 2025 with 17.0 million Total Accounts, an increase of 9%, from 15.7 million as of January 31,

    2/18/25 4:01:00 PM ET
    $HQY
    Real Estate

    HealthEquity Announces Record Year-End HSA Sales Outlook, Presentation at J.P. Morgan Healthcare Conference

    DRAPER, Utah, Jan. 13, 2025 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ:HQY) ("HealthEquity" or the "Company"), the nation's largest health savings account ("HSA") custodian, today announced estimates of HSAs, HSA Assets and Total Accounts for its fiscal year ending January 31, 2025, reflecting a strong sales year with record New HSAs from Sales and strong custodial HSA Asset growth. Estimated HSAs to be approximately 9.8 million by January 31, 2025, up from 8.7 million a year earlier.Estimated HSA Assets to be approximately $31 billion, up from $25.2 billion at the end of fiscal year 2024, with approximately $17 billion of HSA Cash. Invested balances included in the estimated assets a

    1/13/25 9:01:00 AM ET
    $HQY
    Real Estate

    QuidelOrtho Announces Appointment of Two Independent Directors to its Board

    Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/R. Scott Huennekens (Photo: Business Wire) T

    12/10/24 7:00:00 AM ET
    $CTLT
    $HYPR
    $NVST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    $HQY
    $QDEL
    $TPX
    Financials

    Live finance-specific insights

    View All

    HealthEquity Announces Dates to Report Second Quarter Earnings and Presentations at Investor Conferences

    DRAPER, Utah, Aug. 06, 2025 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ:HQY) ("HealthEquity" or the "Company"), the nation's largest health savings account ("HSA") custodian, today announced plans to release its second quarter of fiscal 2026 financial results following the close of regular stock market trading hours on Tuesday, September 2, 2025. Following the news release, HealthEquity management plans to host a conference call for investors on Tuesday, September 2, 2025, at 4:30 p.m. Eastern Time during which management will review the Company's financial results. HealthEquity Second Quarter Fiscal Year 2026 Results Conference CallDate: September 2, 2025Time: 4:30 p.m. Eastern Time /

    8/6/25 9:00:00 AM ET
    $HQY
    Real Estate

    QuidelOrtho Reports Second Quarter 2025 Financial Results

    ― Labs revenue grew 4% as reported and 5% in constant currency ―― Adjusted EBITDA margin improved by 330 basis points; Achieved $100 million annualized cost savings from initiatives announced in 2024 ― ― Company reiterates full-year 2025 financial guidance ― Second Quarter 2025 Results(all comparisons are to the prior year period) Total revenue was $614 million, as reportedNon-respiratory revenue was $567 million, a decrease of 2% both as reported and in constant currency; excluding Donor Screening, non-respiratory revenue grew 1% in constant currencyLabs revenue grew 4% as reported and 5% in constant currencyImmunohematology revenue grew 4% as reported and 3% in constant currencyRespiratory

    8/5/25 4:10:00 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    QuidelOrtho to Report Second Quarter 2025 Financial Results

    SAN DIEGO, July 22, 2025 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for its second quarter 2025 ended June 29, 2025, after the market close on Tuesday, August 5, 2025. Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested

    7/22/25 4:30:00 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $HQY
    $QDEL
    $TPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by QuidelOrtho Corporation

    SC 13G/A - QuidelOrtho Corp (0001906324) (Subject)

    12/6/24 10:11:24 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13D/A filed by QuidelOrtho Corporation

    SC 13D/A - QuidelOrtho Corp (0001906324) (Subject)

    11/21/24 5:10:19 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by QuidelOrtho Corporation

    SC 13G/A - QuidelOrtho Corp (0001906324) (Subject)

    11/14/24 1:28:35 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care